TG Therapeutics, Inc. (TGTX)

TG Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	May 7, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	5,533	4,320	2,416	1,584	2,488	6,703
Market Cap Growth	160.03%	78.80%	52.51%	-36.33%	-62.88%	515.51%
Enterprise Value	5,477	4,233	2,297	1,491	2,159	6,490
Last Close Price	34.85	30.10	17.08	11.83	19.00	52.02
PE Ratio	146.34	184.75	190.66	-	-	-
Forward PE	29.73	45.21	-	-	-	-
PS Ratio	13.12	13.13	10.34	568.84	371.96	44096.70
PB Ratio	22.57	19.43	15.05	27.04	10.49	12.91
P/TBV Ratio	24.88	19.43	15.05	27.41	10.53	12.93
EV/Sales Ratio	14.17	12.87	9.83	535.24	322.82	42698.06
EV/EBITDA Ratio	91.47	100.79	110.20	-	-	-
EV/EBIT Ratio	91.55	100.95	111.33	-	-	-
Debt / Equity Ratio	1.14	1.14	0.69	1.42	0.34	0.08
Debt / EBITDA Ratio	4.25	5.74	4.82	-	-	-
Asset Turnover	-	0.73	0.89	0.01	0.01	0
Inventory Turnover	-	0.51	-	-	-	-
Quick Ratio	-	4.85	5.00	3.04	4.84	6.92
Current Ratio	-	6.25	5.92	3.16	5.06	6.99
Return on Equity (ROE)	-	12.21%	11.57%	-151.36%	-92.03%	-100.14%
Return on Assets (ROA)	-	5.78%	4.93%	-47.61%	-42.87%	-43.36%
Return on Capital (ROIC)	9.99%	7.00%	6.24%	-59.52%	-49.04%	-53.28%
Return on Capital Employed (ROCE)	-	8.60%	7.50%	-	-	-
Earnings Yield	0.71%	0.54%	0.52%	-14.13%	-13.99%	-4.17%
FCF Yield	-	-0.94%	-1.30%	-11.12%	-11.90%	-3.21%
Buyback Yield / Dilution	-9.66%	-7.96%	-9.67%	-2.41%	-14.64%	-30.51%

Updated May 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q